NeoImmuneTech Inc (KOSDAQ: 950220), a US-based clinical-stage T cell-focused biopharmaceutical company, announced on Tuesday that it has named Luke Oh, PhD as its new president and chief executive officer (CEO).
Dr Oh is to succeed Dr Se Hwan Yang, PhD. In the new role, Dr. Oh will head the company from its Rockville headquarters and oversee all of the company's Korea operations.
With more than six years of regulatory experience at the US FDA, Dr Oh has also served as vice-president in charge of Regulatory Development at Samsung Bioepis, senior staff fellow at the US FDA Division of Clinical Pharmacology III and Division of Inflammation and Immune Pharmacology, and in various roles in research and development for leading organisations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences and Vertex Pharmaceuticals.
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
NeuroSense Therapeutics pursues early commercialisation of ALS treatment in Canada
Ananda Developments PLC signs contract for Phase 1 PK study on MRX1
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps